Tetraphase antibiotic reaches patient halfway point in Phase III

Tetraphase Pharmaceuticals (TTPH) has enrolled 50% of the 536 patients that it plans to recruit for the first Phase III trial of its lead antibiotic candidate Eravacycline, which is designed to treat multidrug-resistant (MDR) infections.

The study, called Ignite, is assessing the therapy for complicated intra-abdominal infections.

Tetraphase has also started enrolling patients for a two-part Phase III trial called Ignite 2 for testing Eravacycline for complicated urinary tract infections. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs